We are very pleased to share a new publication of which OMAKASE is a co-author together with expert Spanish epileptologists and hospital pharmacists: a study to determine the economically justifiable price of a new antiseizure medication, to become a cost-effective option in the treatment of focal-onset seizures (FOS) in adult patients with drug-resistant epilepsy (DRE) in Spain.
The treatment and management of DRE is associated with a high economic and clinical burden. Therefore, it is crucial to assess the effectiveness of new drugs to support adequate decision-making and contribute to the sustainability of the healthcare system.
We hope this study will contribute to the performance of holistic value-based pricing and reimbursement evaluations of cenobamate.
